These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36455646)

  • 21. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
    Wulff AB; Nichols CD; Thompson SM
    Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelics: Science sabotaged by Social Media.
    Sellers EM; Romach MK
    Neuropharmacology; 2023 Apr; 227():109426. PubMed ID: 36693562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
    Ledwos N; Rosenblat JD; Blumberger DM; Castle DJ; McIntyre RS; Mulsant BH; Husain MI
    J Clin Psychopharmacol; 2022 Nov-Dec 01; 42(6):581-588. PubMed ID: 36193898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
    Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR
    Pharmacopsychiatry; 2021 Sep; 54(5):240-245. PubMed ID: 34348413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis.
    Leger RF; Unterwald EM
    J Psychopharmacol; 2022 Jan; 36(1):20-30. PubMed ID: 34519567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
    Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J
    J Psychoactive Drugs; 2022; 54(4):309-318. PubMed ID: 34468293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. UK medical students' self-reported knowledge and harm assessment of psychedelics and their application in clinical research: a cross-sectional study.
    Song-Smith C; Jacobs E; Rucker J; Saint M; Cooke J; Schlosser M
    BMJ Open; 2024 Mar; 14(3):e083595. PubMed ID: 38485474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Animal Behavior in Psychedelic Research.
    Odland AU; Kristensen JL; Andreasen JT
    Pharmacol Rev; 2022 Oct; 74(4):1176-1205. PubMed ID: 36180111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
    Johnson MW; Hendricks PS; Barrett FS; Griffiths RR
    Pharmacol Ther; 2019 May; 197():83-102. PubMed ID: 30521880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
    Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D
    Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.